ClinicalTrials.gg
CompletedNCT03498456Updated May 8, 2020

Triple Therapy With Tegoprazan in H. Pylori Positive Patients

A Phase 3 interventional study of Tegoprazan/Amoxicillin/Clarithromycin and Lansoprazole/Amoxicillin/Clarithromycin in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-08.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan after oral administration of the therapy for 7 days, twice daily in H. pylori positive patients.

Read the detailed description

This is a randomized, double blind, active controlled, multicenter, Phase 3 study to demonstrate the non-inferiority of tegoprazan triple therapy (TAC) to lansoprazole triple therapy (LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan in H. pylori positive patients after oral administration of therapy for 7 days, twice daily. After the treatment, UBT test will be conducted to confirm the Helicobacter pylori eradication.

02

Conditions studied

  • Helicobacter Pylori Infection
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • H. pylori positive based on the screening test
  • Peptic ulcer disease

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for H. pylori eradication
  • Prior use of proton pump inhibitors (PPIs), H2 receptor blockers, at a full dosage within 14 days
  • Prior use of H. pylori eradication effective antibiotics, bismuth within 14 days
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Tegoprazan/Amoxicillin/Clarithromycin

    Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg

    Drug: Tegoprazan/Amoxicillin/Clarithromycin

  • Active comparator
    Lansoprazole/Amoxicillin/Clarithromycin

    Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg

    Drug: Lansoprazole/Amoxicillin/Clarithromycin

Interventions

  • DrugTegoprazan/Amoxicillin/Clarithromycin

    Drug pages: Tegoprazan · Amoxicillin · Clarithromycin

    Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.

    Also known as: Tegoprazan triple therapy (TAC)

  • DrugLansoprazole/Amoxicillin/Clarithromycin

    Drug pages: Lansoprazole · Amoxicillin · Clarithromycin

    Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.

    Also known as: Lansoprazole triple therapy (LAC)

06

What researchers measure

Primary outcomes

  1. H. pylori eradication rate

    Subjects will be considered to succeed in achieving H. pylori eradication if subjects's negative UBT test.

    Time frame: 6 weeks

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Dec 2019, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2018
First posted
Apr 13, 2018
StartActual
Jun 28, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Last update
May 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03498456
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Jun 28, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
May 8, 2020

Study contacts

Hwoon Yong Jung, Professor
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegoprazan · Amoxicillin · Clarithromycin

Start the discussion